TABLE 1 CLINICAL TRIALS FOR ANTI-INFLAMMATORY DRUGS
TABLE 2 PATENT EXPIRY OF MAJOR BRANDS
TABLE 3 ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET, BY INDICATION, 2014-2020, ($MILLION)
TABLE 4 ASIA-PACIFIC ARTHRITIS ANTI INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 5 ASIA-PACIFIC RESPIRATORY DISEASES ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 6 ASIA-PACIFIC MULTIPLE SCLEROSIS ANTI INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 7 ASIA-PACIFIC PSORIASIS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 8 ASIA-PACIFIC INFLAMMATORY BOWEL DISEASE ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 9 ASIA-PACIFIC OTHER INFLAMMATORY DISEASES ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 10 ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014-2020 ($MILLION)
TABLE 11 GLOBAL TOP SELLING BIOLOGIC ANTI-INFLAMMATORY BRANDS, 2014 ($MILLION)
TABLE 12 ASIA-PACIFIC ANTI-INFLAMMATORY BIOLOGICS THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 13 ASIA-PACIFIC NSAIDS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 14 GLOBAL TOP SELLING CORTICOSTEROIDS ANTI-INFLAMMATORY BRANDS, 2014 ($MILLION)
TABLE 15 ASIA-PACIFIC CORTICOSTEROIDS ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014-2020 ($MILLION)
TABLE 16 ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY COUNTRY, 2014 2020 ($MILLION)
TABLE 17 JAPAN ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 ($MILLION)
TABLE 18 CHINA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 ($MILLION)
TABLE 19 INDIA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 ($MILLION)
TABLE 20 AUSTRALIA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 ($MILLION)
TABLE 21 SOUTH KOREA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 ($MILLION)
TABLE 22 INDONESIA ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 ($MILLION)
TABLE 23 REST OF ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET BY DRUG CLASS, 2014 2020 ($MILLION)
TABLE 24 PFIZER INC SNAPSHOT
TABLE 25 ABBVIE INC. SNAPSHOT
TABLE 26 JOHNSON & JOHNSON SNAPSHOT
TABLE 27 GLAXOSMITHKLINE SNAPSHOT
TABLE 28 MERCK & CO SNAPSHOT
TABLE 29 NOVARTIS AG SNAPSHOT
TABLE 30 F. HOFFMANN-LA ROCHE AG SNAPSHOT
TABLE 31 ELI LILLY SNAPSHOT
TABLE 32 ASTRAZENECA SNAPSHOT
TABLE 33 AMGEN INC SNAPSHOT

LIST OF FIGURE

FIG. 1 TYPES OF ANTI-INFALMMATORY THERAPEUTICS
FIG. 2 TOP FACTORS IMPACTING ON ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014-2020)
FIG. 3 TOP INVESTMENT POCKETS OF ANTI-INFLAMMATORY THERAPEUTICS MARKET (2014)
FIG. 4 TOP WINNING STRATEGIES IN ANTI-INFLAMMATORY THERAPEUTICS MARKET (2012-2015)
FIG. 5 PORTERS FIVE FORCES ANALYSIS
FIG. 6 VALUE CHAIN OF ANTI-INFLAMMATORY THERAPEUTICS MARKET
FIG. 7 MARKET SHARE ANALYSIS, (2014)
FIG. 8 PFIZER FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
FIG. 9 PFIZER FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 10 PFIZER FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 11 PFIZER SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 12 ABBVIE, INC. FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 13 HUMIRA FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 14 ABBVIE SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 15 JOHNSON & JOHNSON PHARMACEUTICALS SALES BY GEOGRAPHY (2014)
FIG. 16 JOHNSON & JOHNSON SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 17 GLAXOSMITHKLINES FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 18 GLAXOSMITHKLINE FINANCIAL REVENUES BY THERAPY AREA
FIG. 19 GLAXOSMITHKLINE SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 20 MERCK FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 21 MERCK FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 22 MERCK SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 23 NOVARTIS FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 24 NOVARTIS FINANCIAL REVENUES BY SEGMENT (2014)
FIG. 25 NOVARTIS SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 26 ROCHE FIANANCIAL REVENUES BY THERAPEUTIC SEGMENTS (2014)
FIG. 27 ROCHE FINANCIAL REVENUES OF PHARMACEUTICALS BY REGION
FIG. 28 ROCHE SWOT ANALYSIS & STRATEGIC CONCLUSIONS
FIG. 29 ELI LILLY FINANCIAL REVENUES BY BUSINESS SEGMENTS (2014)
FIG. 30 ELI LILLY SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 31 ASTRAZENECA FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 32 ASTRAZENECA FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 33 ASTRAZENECA SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 34 AMGEN FINANCIAL REVENUES BY PRODUCT (2014)
FIG. 35 AMGEN FINANCIAL REVENUES BY YEAR ($MILLION)
FIG. 36 AMGEN SWOT ANALYSIS AND STRATEGIC CONCLUSIONS